Poor
Not Aligned
Patient Risk:
Moderate
Summary
Many extracted claims are not supported by the provided FDA label excerpts (e.g., gabapentin alternatives, antidepressants/topicals, switching and 'common next steps'). One claim is contradicted (fibromyalgia efficacy not established). Discontinuation guidance is directionally aligned but some phrasing is unsupported.
Category Scores
Accurate Statements
Kidney function is relevant for pregabalin and related options.
Supported by renal dosing/eligibility based on creatinine clearance (Section 2.5) and elderly renal-function considerations (Section 8.5).
Unsupported Statements
Pregabalin is commonly prescribed for neuropathic pain.
Label excerpt lists indications but does not support the phrasing that it is 'commonly prescribed' (Section 1).
Pregabalin is commonly prescribed for fibromyalgia.
Efficacy for fibromyalgia has not been established (Section 1).
Pregabalin is used as an add-on for partial-onset seizures.
Label indicates partial onset seizures as an adjunctive therapy context but states efficacy has not been established for adjunctive therapy (Section 1).
Gabapentin is used for similar types of nerve pain as pregabalin.
Provided label sections do not describe gabapentin indications or equivalence to pregabalin.
Gabapentin is often considered a practical alternative to pregabalin.
No label content provided supports comparative 'practical alternative' framing.
Patients sometimes switch between pregabalin and gabapentin to improve side-effect tolerability or convenience.
No label content provided supports switching between pregabalin and gabapentin for tolerability/convenience.
Some antidepressants are used for neuropathic pain even when patients are not being treated for depression.
No antidepressant-related statements are present in provided label excerpts.
Antidepressants may be used as an alternative when pregabalin causes dizziness.
Label notes dizziness/somnolence risk (Section 5.5) but does not mention antidepressants as alternatives.
Antidepressants may be used as an alternative when pregabalin causes drowsiness.
Label notes somnolence (Section 5.5) but does not mention antidepressants as alternatives.
Antidepressants may be used as an alternative when pregabalin causes weight gain.
Label notes weight gain (Section 5.8) but does not mention antidepressants as alternatives.
Antidepressants may be used as an alternative when a patient prefers a different mechanism of action.
No label content supports antidepressants as mechanism-preference alternatives.
Topical treatments can sometimes reduce the need for systemic medicine for some localized neuropathic pain syndromes.
No topical-treatment content is present in provided label excerpts.
Topical suitability depends on the pain location and cause.
No topical-treatment guidance present in provided label excerpts.
Common next steps when pregabalin is not working well or causes side effects include switching to gabapentin or another nerve-pain medicine.
No label content provided gives switching guidance to gabapentin or other nerve-pain medicines in response to efficacy/side effects.
Common next steps when pregabalin is not working well or causes side effects include adjusting the dose or titration schedule under medical guidance.
Renal dose adjustment is described (Section 2.5), but the label excerpt does not support side-effect/inefficacy-driven titration-schedule change language as stated.
Common next steps when pregabalin is not working well or causes side effects include changing to a different drug class.
No label content provided supports class-switching as a 'next step.'
Common next steps when pregabalin is not working well or causes side effects include using combination therapy only if appropriate for the diagnosis and risk factors.
No combination-therapy decision rules are provided in the excerpts.
Switching from pregabalin is usually done in a planned way rather than abruptly stopping.
Label supports tapering gradually rather than abrupt/rapid discontinuation (Section 5.6), but does not describe 'switching' strategy.
A prescriber may overlap and taper pregabalin to reduce withdrawal-type symptoms.
Label excerpt specifies gradual taper timing (minimum 1 week) but does not mention overlap.
Tapering pregabalin is done to avoid loss of seizure/pain control.
Section 5.6 describes reducing discontinuation symptoms and notes increased seizure frequency risk with rapid discontinuation, but the specific rationale 'avoid loss of seizure/pain control' is not stated.
The most effective pregabalin alternative depends on the reason the patient takes it (nerve pain type vs fibromyalgia vs seizures).
Label provides indications and notes lack of established efficacy for fibromyalgia and adjunctive partial onset seizures, but does not provide 'most effective alternative' selection guidance.
The most effective pregabalin alternative depends on the patient’s current dose and response.
No labeling content provided supports alternative selection based on current dose/response.
The most effective pregabalin alternative depends on the side effects the patient has had.
Label discusses risks but does not provide alternative-selection guidance based on side effects.
The most effective pregabalin alternative depends on kidney function.
Kidney function affects pregabalin dosing/eligibility (Section 2.5), but the excerpt does not address choosing an 'alternative' based on renal function.
The most effective pregabalin alternative depends on other medicines the patient takes.
Section 7 provides interaction likelihood information, but the excerpt does not support alternative selection guidance based on concomitant medications.
Contradictions
Low
AI Statement
Pregabalin is commonly prescribed for fibromyalgia.
Label Reference
Section 1: 'Efficacy of pregabalin extended-release tablets has not been established for the management of fibromyalgia...'
Important Omissions
When discussing use for partial-onset seizures and fibromyalgia, the label states efficacy has not been established for these contexts; the extracted claims do not consistently reflect this limitation.
Importance:
Moderate
Any discussion of alternatives/switching would need label-consistent constraints (e.g., renal dosing eligibility, tapering rather than abrupt discontinuation); the extracted claims propose multiple alternative categories without label support.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Multiple claims propose specific alternative approaches (switching to gabapentin, antidepressants, topical treatments, class changes, combination-therapy decision rules) that are not supported by the provided labeling excerpts, which could lead to label-inconsistent use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Numerous extracted claims are absent or unsupported by the provided FDA label excerpts, and one claim is contradicted (fibromyalgia efficacy not established).
Suggested Improvement
Limit statements to label-supported indications and labeled limitations (e.g., fibromyalgia efficacy not established; partial-onset seizures adjunctive efficacy not established per provided excerpt). For discontinuation, use the label’s tapering guidance (minimum 1 week rather than abrupt discontinuation) without adding unsupported overlap/switching/alternative-class recommendations. Do not assert alternatives (gabapentin, antidepressants, topical treatments) or 'common next steps' unless those are explicitly described in the provided labeling.